Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

JAMA

Volumn 282, Issue 17, 1999, Pages 1627-1632

  Dornadula, Geethanjali ^a   Zhang, Hui ^a   VanUitert, Bonnie ^a   Stern, John ^b   Livornese, Lawrence ^a   Ingerman, Mark J ^a   Witek, James ^c   Kedanis, Richard J ^a   Natkin, Jaan ^a   DeSimone, Joseph ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRION; VIRUS REPLICATION;

EID: 0033520673     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.17.1627     Document Type: Article

References (39)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-728.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;3:117-122.
6. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-190.
7. Montaner JSG, Reiss P, Cooper D, et al. A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA. 1998;279:930-937.
8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278: 1291-1295.
9. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science. 1997;278:1295-1300.
10. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197.
11. Zhang H, Dornadula G, Beumont M, et al. HIV-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med. 1998;339:1803-1839.
12. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
13. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
14. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276: 960-964.
15. Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 1999;353:119.
16. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-1554.
17. LaFeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. J Infect Dis. 1998;177:235-238.
18. Martinez MA, Cababa M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged depression of plasma viremia. Virology. 1999;256:180-187.
19. Pomerantz RJ, delaMonte SM, Donegan SP, et al. Human immunodeficiency virus infection of the uterine cervix. Ann Intern Med. 1988;108:321-327.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
21. Zhang H, Zhang Y, Spicer TP, et al. Reverse transcription takes place within extracellular HIV-1 virions. AIDS Res Hum Retroviruses. 1993;9:1287-1296.
22. Zhang H, Dornadula G, Wu Y, et al. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals. J Virol. 1996;70:628-634.
23. Zhang H, Dornadula G, Pomerantz RJ. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments. J Virol. 1996;70:2809-2824.
24. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve along term response to therapy. AIDS. 1998;12:1619-1624.
25. Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59-F62.
26. Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS. 1998; 12:1398-1399.
27. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340:1683.
28. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999; 13:F79-F86.
29. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med. 1999;340:1672-1674.
30. Pomerantz RJ. HIV in semen and other reservoirs during effective HAART. HIV Adv Res Ther. 1999; 9:17-24.
31. + T-cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
32. Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med. 1987;317:278-286.
33. Enting RH, Hoetelmans RMW, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS. 1998;12:1941-1955.
34. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions. J Virol. 1996;70:3098-3107.
35. Zhang Z-Q, Schuler T, Wietgrefe S, et al. Sexual transmission and propagation of SIV and HIV-1 in activated and quiescent T cells. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; February 1-4, 1999; Chicago, Ill. Abstract 206.
36. Lewin SR, Vesanen M, Hurley KA, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol. 1999;73:6099-6103.
37. Markowitz M, Vesanan M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:525-537.
38. Grossman Z, Tolis M, Feinberg M, et al. Ongoing HIV dissemination during HAART. Nat Med. 1999; 5:1099-1103.
39. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651-655.